After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...